Abstract:Epacadostat (EPA), the most advanced inhibitor targeting the indoleamine 2,3-dioxygenase 1 (IDO1), is a critical endogenous metabolic immune regulator. In preclinical melanoma models [1], EPA potentiated the antitumor efficacy of immune checkpoint blockers (ICB) in comparison to ICB monotherapy. Phase I/II clinical trials proved the excellent safety and significant IDO1 targeting ability of EPA [2]. Much to the disappointment, combing EPA with Keytruda (anti-PD-1 inhibitor) exerted zero numerical progression-free survival benefit versus Keytruda alone in a subsequent Phase III randomized clinical study (NCT02752074) in unresectable or metastatic melanoma patients [3]. Despite many reasons were blamed for this blockbuster failure such as dosing regimen and experimental designs, the poor pharmacokinetics of EPA is neglected [1]. Piggybacked by our previous success using sphingomyelin (SM)-derived drug nanotherapeutic strategy [4], recently, we developed a SM-derived EPA nanovesicle. The SM-EPA conjugate was bridged by an oxime-ester bond that is highly responsive to hydrolase cleavage in tumors [5]. Following the spontaneous self-assembly into liposomal nanovesicle (Epacasome), EPA was securely packaged in the lipid bilayer. We showed that Epacasome strengthened IDO1 suppression by reducing the production of kynurenine, and promoted T cell proliferation in a co-culture setting. Also, it markedly increased the intracellular uptake via clathrin-mediated endocytosis with highly efficient drug release inside cancer cells. Systematic pharmacokinetic and biodistribution studies demonstrated that free EPA was eliminated from the blood rapidly with a T 1/2 = 0.15 h. However, Epacasome significantly extended the circulation T 1/2 to ~4.72 h, drastically increasing area under curve (AUC: 1196.55 vs 7.81 μg/ml*h), mean residence time (MRT, 6.82 vs 0.22 h), and dramatically decreased volume of distribution (1.1 vs 5.97 μg/(μg/ml)). The improved pharmacokinetics allowed Epacasome a higher chance for tumor uptake based on the enhanced permeability and retention effect, resulting in 46.3-fold more EPA delivery to tumors compared to free EPA. More strikingly, Epacasome deepened tumor penetration and distribution, which are vital for improved IDO1 inhibition in tumors. Epacasome was superior to free EPA in reducing the tumor growth and prolonging mouse survival. It also synergized with anti-PD-1 inhibitor to further fortify the IFN-γ and granzyme-B-mediated cytotoxic T lymphocytes (CTLs) immunity. Meanwhile, this combination regimen repolarized macrophage to inflammatory M1 phenotype, attenuated granulocyte myeloid-derived suppressor cells and the Foxp3 + Tregs, and enhanced CD80 + /CD86 + and CD103 + dendritic cells in B16-F10 melanoma model. These improved anti-melanoma efficacy and immune responses were found to be CD8 T cell dependent and attributed to the boosted IDO1 inhibition as reflected by the greatly increased tryptophan/kynurenine ratios in both plasma and tumor.

Sphingomyelin-derived epacadostat nanovesicle enhances IDO1 inhibition for improved melanoma combination immunotherapy

Sphingomyelin-derived nanovesicles for the delivery of the IDO1 inhibitor epacadostat enhance metastatic and post-surgical melanoma immunotherapy

Bimetallic Peroxide-Based Nanotherapeutics for Immunometabolic Intervention and Induction of Immunogenic Cell Death to Augment Cancer Immunotherapy

Chemo-immunotherapy by nanoliposomal epacadostat and docetaxel combination to IDO1 inhibition and tumor microenvironment suppression

Synergistic Transcutaneous Immunotherapy Enhances Antitumor Immune Responses through Delivery of Checkpoint Inhibitors.

Reversing the negative effect of adenosine A1 receptor-targeted immunometabolism modulation on melanoma by a co-delivery nanomedicine for self-activation of anti-PD-L1 DNAzyme

Achieving Immune Activation by Suppressing the IDO1 Checkpoint with Sono-Targeted Biobromination for Antitumor Combination Immunotherapy

Tumor Microenvironment‐Activated Nanocomposite for Self‐Amplifying Chemodynamic/Starvation Therapy Enhanced IDO‐Blockade Tumor Immunotherapy

Strategies of Combination Drug Delivery for Immune Checkpoint Blockades.

Phase 1/2 study of epacadostat in combination with ipilimumab in patients with unresectable or metastatic melanoma

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Reshaping hypoxia and silencing CD73 via biomimetic gelatin nanotherapeutics to boost immunotherapy

Design of a targeted dual drug delivery system for boosting the efficacy of photoimmunotherapy against melanoma proliferation and metastasis

Charge convertible biomimetic micellar nanoparticles for enhanced melanoma-targeted therapy through tumor cells and tumor-associated macrophages dual chemotherapy with IDO immunotherapy

Dual‐Targeting Nanoliposome Improves Pro‐inflammatory Immunomodulation of the Tumor Microenvironment

IDO-inhibitor potentiated immunogenic chemotherapy abolishes primary tumor growth and eradicates metastatic lesions by targeting distinct compartments within tumor microenvironment

Dendritic nanomedicine enhances chemo-immunotherapy by disturbing metabolism of cancer-associated fibroblasts for deep penetration and activating function of immune cells

A Dual‐Bioresponsive Drug‐Delivery Depot for Combination of Epigenetic Modulation and Immune Checkpoint Blockade

Combination of Chidamide-Mediated Epigenetic Modulation with Immunotherapy: Boosting Tumor Immunogenicity and Response to PD-1/PD-L1 Blockade

Sialic Acid‐Functionalized Pyroptosis Nanotuner for Epigenetic Regulation and Enhanced Cancer Immunotherapy

A Redox-Triggered Autophagy-Induced Nanoplatform with PD-L1 Inhibition for Enhancing Combined Chemo-Immunotherapy